Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection

Infection and Immunity

Volumn 69, Issue 1, 2001, Pages 245-251

  Gicheru, M M ^a   Olobo, J O ^a   Anjili, C O ^a   Orago, A S ^a   Modabber, F ^a   Scott, P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; IMMUNE RESPONSE; IMMUNITY; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-12; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; VACCINATION;

EID: 0035167274     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.1.245-251.2001     Document Type: Article

References (33)

1. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
2. Experimental infection of domestic goats with Leishmania major through bites of infected Phlebotomus duboscqi and needle inoculation of culture-derived promastigotes
3. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up
4. Isolation of Leishmania major from a naturally infected vervet monkey (Cercopithecus aethiops) caught in Kiambu District
5. Immunologic patterns associated with cure in human American cutaneous leishmaniasis
6. Evaluation of the stability and immunogenecity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis
7. The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis
8. A role for Lyt2+ T cells in resistance to cutaneous leishmaniasis in immunized mice
9. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease
10. Visceral leishmaniasis in vervet monkeys: Immunological responses during asymptomatic infections
11. Leishmania major: The suitability of East African nonhuman primates as animal models for cutaneous leishmaniasis
12. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
13. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
14. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets
15. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages
16. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
17. Experimental transmission of Leishmania major to velvet monkeys (Cercopithecus aethiops) by bites of Phlebotomus duboscqi (Diptera: Psychodidae)
18. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil
19. Vaccines against leishmaniasis
20. Expression cloning of a protective Leishmania antigen
21. Gamma interferon response in secondary Leishmania major infection: Role of CD8+ T cells
22. Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major
23. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63)
24. Delayed-type hypersensitivity responses in vervet monkeys self-cured from experimental cutaneous leishmaniasis
25. IFN-gamma and delayed-type hypersensitivity are associated with cutaneous leishmania- sis in vervet monkeys following secondary rechallenge with Leishmania major
26. Mitogenic responses of peripheral blood mononuelear cells of vervet monkeys (C. aethiops). Apparent role of adherent cells
27. Immunologic mechanisms in Leishmania
28. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
29. IL-12 as an adjuvant for cell-mediated immunity
30. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
31. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95
32. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
33. Administration of recombinant human interleukin 12 to chronically SIV mac-infected rhesus monkeys